Form 4: BioLife Solutions CTO Sells Shares for Tax Obligations

BioLife Solutions' Chief Technology Officer, Sean Werner, sold 72 shares of common stock at $26.83 per share to cover tax withholding obligations.

Summary

• Sean Werner, Chief Technology Officer of BioLife Solutions Inc. (BLFS), reported a sale of common stock.
• The transaction involved the disposition of 72 shares of common stock.
• The shares were sold at a price of $26.83 per share.
• The sale occurred on September 11, 2025.
• Following this transaction, Sean Werner directly beneficially owns 26,312 shares of common stock.
• The sale was executed pursuant to a Rule 10b5-1(c) trading plan, which was adopted on September 1, 2021.
• The purpose of the sale was to satisfy tax withholding obligations related to the vesting of restricted stock.

Sentiment

Score: 5

Explanation: The filing reports a routine insider stock sale for tax withholding purposes under a pre-arranged 10b5-1 plan, which is a neutral event and does not indicate a positive or negative sentiment towards the company's future.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sale reported was made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person effective as of September 1, 2021, to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans for tax withholding purposes, are common occurrences for executives in publicly traded companies across all industries. They typically do not reflect a change in management's outlook on the company's prospects but rather a routine administrative event.

Stakeholder Impact

• Shareholders: The sale of 72 shares by a Chief Technology Officer is a very small transaction relative to the company's total outstanding shares and is unlikely to have any material impact on shareholder value or perception.
• Employees: No direct impact on employees is indicated by this routine transaction.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of a small number of shares by a company officer to cover tax withholding obligations under a pre-established 10b5-1 plan. Such a transaction does not reflect a change in the officer's outlook on the company's fundamentals or future prospects and is not indicative of any material positive or negative developments. Therefore, it provides no basis to alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

BioLife Solutions, BLFS, Sean Werner, CTO, Form 4, Insider Transaction, Stock Sale, 10b5-1 Plan, Tax Withholding